Screening and habituation of functional electrical stimulation-leg cycle ergometry for individuals with spinal cord injury: a pilot study.
Amira E Tawashy, Janice J Eng, Andrei V Krassioukov...
https://pubmed.ncbi.nlm.nih.gov/19265757/Actively Recruiting
Led by University of British Columbia · Updated on 2026-02-27
60
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating the safety and effectiveness of non-invasive transcutaneous spinal cord stimulation TSCS to improve lower urinary tract, bowel, sexual, and cardiovascular function, as well as reduce spasticity, in adults with subacute and chronic spinal cord injury SCI. This Phase II clinical trial aims to understand how TSCS impacts quality of life and bladder function in individuals with SCI at spinal segments C5-T10. The study includes participants with motor-complete SCI and documented impaired bladder function. The investigational device, SCONE174, delivers electrical stimulation through the skin to activate spinal neural circuits related to pelvic floor and bladder control. Participants will be randomly assigned to one of two groups Group 1 will receive therapeutic TSCS combined with conventional rehabilitation for 8 weeks, followed by an additional 8 weeks of TSCS therapy Group 2 will initially receive sham stimulation with rehabilitation for 8 weeks and then switch to therapeutic TSCS for 8 weeks. Therapy sessions last one hour, three times a week, with rehabilitation 3-4 hours a day, five days a week. Each participant will attend 58 visits over approximately 33 weeks for assessments, therapy, and follow-up. Evaluations include bladder function, bowel movements, sexual health, cardiovascular monitoring, spasticity, and quality of life questionnaires. Researchers will measure changes in Neurogenic Bladder Symptom Score, voiding efficiency, and bowel movement timing, among others. Follow-up assessments will be conducted 8 weeks after treatment ends to assess lasting effects of TSCS.
CONDITIONS
Noninvasive Spinal Cord Stimulation for Early SCI
A
Andrea Maharaj, BSc
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of British Columbia
Lead Sponsor
United States Department of Defense
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 8 to 16 weeks
Participants receive non-invasive transcutaneous spinal cord stimulation (TSCS) therapy to improve bladder function. Group 1 receives TSCS therapy for 16 weeks, and Group 2 receives sham stimulation for 8 weeks followed by 8 weeks of TSCS therapy.
Three visits per week, 1 hour per session, for up to 16 weeks
Duration - 8 weeks
Participants are assessed for persisting effects of TSCS after stopping therapy, including bladder, bowel, sexual function, and quality of life assessments.
1 follow-up visit after cessation of treatment
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Amira E Tawashy, Janice J Eng, Andrei V Krassioukov...
https://pubmed.ncbi.nlm.nih.gov/19265757/Fiona Charlson, Mark van Ommeren, Abraham Flaxman...
https://pubmed.ncbi.nlm.nih.gov/31200992/P M Faaborg, P Christensen, A Krassioukov...
https://pubmed.ncbi.nlm.nih.gov/24777164/Keren Lehavot, Simon B Goldberg, Jessica A Chen...
https://pubmed.ncbi.nlm.nih.gov/29936598/J M Stone, M Nino-Murcia, V A Wolfe...
https://pubmed.ncbi.nlm.nih.gov/2389723/Edsel M Abud, Ronaldo M Ichiyama, Leif A Havton...
https://pubmed.ncbi.nlm.nih.gov/25694482/I Eltorai, R Kim, M Vulpe...
https://pubmed.ncbi.nlm.nih.gov/1598177/Rahul Sachdeva, Tom E Nightingale, Andrei V Krassioukov
https://pubmed.ncbi.nlm.nih.gov/31109053/Donna M Dryden, L Duncan Saunders, Phillip Jacobs...
https://pubmed.ncbi.nlm.nih.gov/16294090/A Esclarín De Ruz, E García Leoni, R Herruzo Cabrera
https://pubmed.ncbi.nlm.nih.gov/10992382/University of British Columbia
Lead Sponsor
United States Department of Defense
Collaborating Sponsor